Hydroxy, Bonded Directly To Carbon, Attached Directly Or Indirectly To The Acyclic Carbon Or Chain By Acyclic Nonionic Bonding (e.g., Beta Hydroxy Phenethylamines, Etc.) Patents (Class 514/653)
-
Publication number: 20110027324Abstract: The present invention provides methods for treating MDD. In general, the methods comprise administering to a patient in need thereof a daily dose of about 50 mg ODV or an equivalent amount of a pharmaceutically acceptable salt thereof. In certain embodiments, a patient in need of treatment is characterized by a primary diagnosis of MDD. In some embodiments, the dose is administered as a single daily dose. In one set of embodiments, the methods involve administering an oral dosage form comprising the succinate salt of ODV.Type: ApplicationFiled: December 10, 2007Publication date: February 3, 2011Applicant: Wyeth LLCInventors: Robert Michael Poole, Karen Astrid Tourian
-
Publication number: 20110021636Abstract: A method for highly efficiently preparing high purity crystals of 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chloro-phenyl]-ethyl]-1,3-propanediol hydrochloride. The method involves dissolving 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol in a mixed solvent comprising a solvent in which its hydrochloride is highly soluble and a solvent in which its hydrochloride is less soluble, to prepare a solution of 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol; and then adding hydrochloric acid to the resulting solution with stirring, to crystallize the hydrochloride of 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chloro-phenyl]ethyl]-1,3-propanediol.Type: ApplicationFiled: March 18, 2009Publication date: January 27, 2011Applicant: Kyorin Pharmaceutical Co., Ltd.Inventors: Hidetaka Komatsu, Hiroya Satoh
-
Publication number: 20110015159Abstract: Agonists of vascular endothelial sphingosine-1-phosphate receptors are described. Compounds such as FTY720 can be phosphorylated by sphingosine kinase-2 into the phosphorylated forms which serve as sphingosine-1-phosphate receptor agonists. The vascular endothelial sphingosine-1-phosphate receptor agonists are employed in methods of treating a mammal for vascular permeability disorders and unwanted vascular endothelial cell apoptosis, and for the growth of new blood vessels. The sphingosine-1-phosphate receptor agonists can be used for the manufacture of a medicament for treating vascular permeability disorders and unwanted vascular endothelial cell apoptosis, and for the growth of new blood vessels.Type: ApplicationFiled: September 30, 2010Publication date: January 20, 2011Applicant: UNIVERSITY OF CONNECTICUTInventors: Timothy Hla, Teresa Sanchez, Kevin Patrick Claffey, Ji-Hye Paik
-
Publication number: 20110003895Abstract: Described herein are methods for the treatment of an ophthalmic disease or disorder comprising the administration of non-retinoid visual cycle modulators.Type: ApplicationFiled: July 2, 2010Publication date: January 6, 2011Applicant: ACUCELA, INC.Inventors: Ryo Kubota, Nancy Boman, Claes Bavik, Ian L. Scott
-
Publication number: 20110003897Abstract: Disclosed herein are polar drug particles with surface-trapped hydrofluoroalkane-philes and methods of making the same.Type: ApplicationFiled: October 31, 2008Publication date: January 6, 2011Applicant: WAYNE STATE UNIVERSITYInventors: Sandro R.P. Da Rocha, Libo Wu
-
Publication number: 20100330150Abstract: The present invention is directed to pharmaceutical compositions comprising a plurality of taste-masked high-dose/low-dose drug-containing microparticles, dosage forms comprising such pharmaceutical compositions (such as an orally disintegrating tablet), and methods of making the pharmaceutical compositions and dosage forms of the present invention. Dosage forms comprising the pharmaceutical compositions of the present invention are improved homogeneous blends of high-dose and low-dose drugs which provide for more convenient and palatable administration of drug combinations, for example for treating pain, hyperglycemia, cardiovascular disease, and allergies.Type: ApplicationFiled: May 3, 2010Publication date: December 30, 2010Inventors: Gopi Venkatesh, Michael Gosselin, James Clevenger, Jin-Wang Lai
-
Publication number: 20100330172Abstract: A pharmaceutical formulation comprising desvenlafaxine having an MMD of between about 5 ?m and about 100 ?m, or a pharmaceutically acceptable salt thereof, and at least one matrix rate-controlling pharmaceutically acceptable polymer, solid unit dosage form containing it, methods for preparing such a formulation and for its use to treat depression and related disorders and diseases.Type: ApplicationFiled: October 13, 2008Publication date: December 30, 2010Applicant: ALPHAPHARM PTY LTDInventors: Brett Antony Mooney, Panagiotis Keramidas
-
Publication number: 20100324000Abstract: The present disclosure relates to 4-(2-amino-1-hydroxyethyl)phenol derivatives of formula (I) as well as pharmaceutical compositions comprising them, and their use in therapy as agonists of the ?2 adrenergic receptor.Type: ApplicationFiled: November 10, 2008Publication date: December 23, 2010Inventors: Victor Giulio Matassa, Carlos Puig Duran, Maria Prat QuiƱones, Laia Sole Fue, Oriol Llera Soldevila
-
Publication number: 20100323978Abstract: The present invention relates to a delivery system for ophthalmic drugs, and more particularly, to a non aqueous oil delivery system. Low concentrations of ophthalmic drugs suspended in an oil vehicle delivery system are as therapeutically effective in man and animals as the corresponding higher concentrations of ophthalmic drugs that are commercially used in aqueous solutions. Eye drops that utilize this nonaqueous oil delivery system, when used in man, are comfortable to use and produce little ocular irritation, have a longer shelf-life, low systemic toxic potential, and only short term blurring of vision. Using this nonaqueous oil delivery system, a single drop of ophthalmic drug with a concentration that is 10 times less than the same drug used in commercially available aqueous eye drops is as effective as the commercially available aqueous ophthalmic eye drops that require many applications to be effective.Type: ApplicationFiled: June 22, 2009Publication date: December 23, 2010Inventor: Calvin Hanna
-
Publication number: 20100316723Abstract: Provided are electrokinetically-altered fluids (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for using same in treating inflammation or at least one symptom thereof. The electrokinetically-altered fluid compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents.Type: ApplicationFiled: April 30, 2010Publication date: December 16, 2010Applicant: Revalesio CorporationInventors: Richard L. Watson, Anthony B. Wood, Gregory J. Archambeau
-
Publication number: 20100317627Abstract: S1P receptor agonists are useful for the treatment of hepatitis C or chronic hepatitis C (HCV).Type: ApplicationFiled: August 19, 2010Publication date: December 16, 2010Inventors: Volker BRINKMANN, Gilles FEUTREN
-
Publication number: 20100310664Abstract: Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating diabetes and diabetes-associated conditions or disorders (e.g., insulin resistance), or symptoms thereof. Provided are electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes).Type: ApplicationFiled: April 27, 2010Publication date: December 9, 2010Applicant: Revalesio CorporationInventors: Richard L. Watson, Anthony B. Wood, Gregory J. Archambeau
-
Publication number: 20100311767Abstract: The present invention relates to a method for the treatment of an amyloidosis such as Alzheimer's disease in a subject in need thereof, characterized in that it comprises administering an agonist of the P/Q type voltage-gated presynaptic calcium channel to said subject.Type: ApplicationFiled: February 27, 2008Publication date: December 9, 2010Applicant: ABBOTT GMBH & CO. KGInventors: Volker Nimmrich, Stefan Barghorn, Ulrich Ebert, Heinz Hillen, Gerhard Gross, Andreas Draguhn, Claus Bruhl, Christine Grimm, Carsten Krantz
-
Publication number: 20100311841Abstract: Therapeutic compounds based on synthetic sphingolipid analogs are provided, particularly alkylthiophenyl substituted ceramide analogs, suitable for treating degenerative, infectious, and other diseases.Type: ApplicationFiled: November 6, 2008Publication date: December 9, 2010Inventors: Arie Dagan, Shimon Gatt, Shimon Slavin
-
Publication number: 20100310547Abstract: The present invention relates generally to the field of inflammatory diseases of the peripheral nervous system. More particularly, it concerns methods for treating inflammatory diseases of the peripheral nervous system by modulating sphingosine-1-phosphate receptor activity. In one embodiment, the present invention provides a method of treating a subject with chronic inflammatory demyelinating polyneuropathy (CIDP) or other autoimmune neuropathies comprising administering to the subject an effective amount of FTY720.Type: ApplicationFiled: August 17, 2007Publication date: December 9, 2010Inventor: Betty C. Soliven
-
Publication number: 20100311842Abstract: Use of 1-phenyl-3-dimethylaminopropane compounds for the production of medicaments for treating neuropathic pain, preferably polyneuropathic pain, also preferably diabetic neuropathic pain, more preferably diabetic peripheral neuropathic pain, and furthermore preferably for treating diabetic peripheral neuropathy.Type: ApplicationFiled: August 4, 2010Publication date: December 9, 2010Applicant: GRUENENTHAL GmbHInventors: Thomas CHRISTOPH, Elmar Friderichs, Babette-Yvonne Koegel, Murielle Meen
-
Publication number: 20100311710Abstract: The present invention relates to new cyclobutanemethanamine inhibitors of monoamine reuptake, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: December 4, 2009Publication date: December 9, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar, Manouchehr M. Shahbaz
-
Patent number: 7846973Abstract: The present invention relates to the preparation of a ?2 adrenergic agonist in crystalline salt form. In particular the invention relates to preparation of a crystalline salt of compound (I) in particular a crystalline monohydrochloride salt. The invention also relates to a new crystalline form (polymorph) of the monohydrochloride salt of compound (Ia) and a process for preparing it.Type: GrantFiled: March 30, 2005Date of Patent: December 7, 2010Assignee: Theravance, Inc.Inventors: Darren Michael Caine, Ian Leonard Paternoster, Peter David Penberthy Shapland
-
Publication number: 20100305101Abstract: A method of identifying livestock animal subgroups of the same species, from a group of livestock animals of the same species wherein the subgroup has similar genetic predispositions for response to Zilpaterol Hydrochloride (ZH) treatment with respect to marbling, HCW gain, REA size gain, DDMI, % EBF, and YG's. The genetic potential of each animal to respond to ZH treatment is established by determining the LeptinArg25Cys genotype and segregating individual animals into subgroups based upon the LeptinArg25Cys genotype.Type: ApplicationFiled: April 28, 2010Publication date: December 2, 2010Inventor: Foley Leigh Shaw Marquess
-
Publication number: 20100303918Abstract: Provided are compositions and methods for treating lung or respiratory disorders or conditions characterized by airflow obstruction or limitation, or a symptom thereof (e.g., asthma, rhinitis, allergic rhinitis, and chronic obstructive pulmonary disease (COPD) and COPD-associated conditions (e.g., bronchitis, emphysema, asthma), emphysema, pneumonia, bronchitis, influenza, SARS, tuberculosis, and whooping cough (pertussis), and the like) in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically altered fluid (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures as disclosed herein. In certain aspects, the methods comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential and/or conductance, membrane proteins (e.g., membrane receptors, (e.g.Type: ApplicationFiled: May 3, 2010Publication date: December 2, 2010Applicant: Revalesio CorporationInventors: Richard L. Watson, Anthony B. Wood, Gregory J. Archambeau
-
Patent number: 7842729Abstract: Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.Type: GrantFiled: June 3, 2005Date of Patent: November 30, 2010Assignees: The United States of America as represented by the Department of Health and Human Services, Sequella, Inc.Inventors: Marina Nikolaevna Protopopova, Richard Edward Lee, Richard Allan Slayden, Clifton E. Barry, III, Elena Bogatcheva, Leo Einck
-
Patent number: 7838562Abstract: Agonist of vascular endothelial sphingosine-1-phosphate receptors are described. Compounds such as FTY720 can be phosphorylated by sphingosine kinase-2 into the phosphorylated forms which serve as sphingosine-1-phosphate receptor agonists. The vascular endothelial sphingosine-1-phosphate receptor agonists are employed in methods of treating a mammal for vascular permeability disorders and unwanted vascular endothelial cell apoptosis, and for the growth of new blood vessels. The sphingosine-1-phosphate receptor agonists can be used for the manufacture of a medicament for treating vascular permeability disorders and unwanted vascular endothelial cell apoptosis, and for the growth of new blood vessels.Type: GrantFiled: June 18, 2004Date of Patent: November 23, 2010Assignee: University of ConnecticutInventors: Timothy Hla, Teresa Sanchez, Kevin Patrick Claffey, Ji-Hye Paik
-
Publication number: 20100291160Abstract: Non-invasive drug delivery systems useful for the absorption of therapeutically active agents through the epithelial membrane are described. The non-invasive drug delivery system delivers a therapeutic active agent with an ionizable, or ionized, metal, transition metal or metal-containing vehicle. The non-invasive drug delivery system may also have a pH adjustable vehicle which facilitates the absorption of the therapeutic agents by altering the pH of the non-invasive drug delivery system at the site of administration. Also disclosed is a method for the pH āsweepingā of the administered therapeutic active agent to provide a consistent and reproducible absorption of the active agent. Certain formulations utilize low doses of active agents without altering the active agents from their current or previous form.Type: ApplicationFiled: May 12, 2010Publication date: November 18, 2010Inventors: David R. Carver, Troy G. Fohrman, Sean William Reynolds
-
Publication number: 20100288665Abstract: A pharmaceutical formulation of therapeutically effective amounts of acetaminophen, ibuprofen, and a sympathomimetic drug, such as pseudoephedrine (or its prodrug), or phenylephrine used in the treatment of cold and flu-like symptoms. Such symptoms may include fever, pain, nasal congestion, sinus congestion, runny nose, sore throat, myalgia, ear pressure and fullness, and headache. The formulation further includes various excipients used in the formulation process.Type: ApplicationFiled: July 23, 2008Publication date: November 18, 2010Applicant: Kingsway Pharmaceuticals Inc.Inventor: Mark Andrew Lomaga
-
Publication number: 20100291027Abstract: Disclosed herein are compositions that exhibit viscosities suitable for injectable formulations. The compositions comprise bioactive agent-loaded microparticles and hyaluronic acid or a salt thereof in a suitable liquid pharmaceutical carrier. Also disclosed are methods of making and using the compositions.Type: ApplicationFiled: May 13, 2010Publication date: November 18, 2010Inventor: Jason Campbell
-
Publication number: 20100291208Abstract: The present invention relates to controlled porous osmotic pump tablets of high permeable drugs and the preparation process thereof. The controlled porosity osmotic pump tablets do not need to be drilled by laser, but provides controlled porosity for drug release by adding a suitable quantity of pore-forming agents into the semipermeable membrane. In specific embodiments, the present invention relates to controlled porous osmotic pump tablets comprising venlafaxine or metoprolol or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: October 16, 2007Publication date: November 18, 2010Inventors: Jingang Wang, Haisong Jiang
-
Publication number: 20100286224Abstract: The use of ?-adrenergic inverse agonists provides a new and highly efficient way of treating a number of pulmonary airway diseases, including asthma, emphysema, and chronic obstructive pulmonary diseases. In general, such a method comprises administering a therapeutically effective amount of a ?-adrenergic inverse agonist to the subject to treat the pulmonary airway disease. Particularly preferred inverse agonists include nadolol and carvedilol. In addition, methods are described for long-term administration of such inverse agonists and for determining the suitability of patients for long-term inverse agonist therapy.Type: ApplicationFiled: May 5, 2009Publication date: November 11, 2010Inventor: Richard A. Bond
-
Publication number: 20100286164Abstract: Aspects of the invention relate to substituted aryl propylamino-oxy-analogs and uses thereof. Aspects of the invention relate to compositions that are inhibitors of ?-secretase and uses thereof for treating subjects having, or at risk of developing, Alzheimer's disease.Type: ApplicationFiled: October 10, 2008Publication date: November 11, 2010Applicant: The Brigham and Women's Hospital, IncInventors: Corinne Elizabeth Augelli-Szafran, Michael S. Wolfe, Han-Xun Wei
-
Publication number: 20100278741Abstract: Provided are novel compositions and analogs which are useful in a number of applications, indications and diseases, as well as for monitoring pharmakinetics and patient management. These compounds and analogs are applicable to treating tumors of the central nervous system, e.g., glioblastoma (GBM).Type: ApplicationFiled: August 31, 2009Publication date: November 4, 2010Inventors: Sarah Spiegel, Robert Elliot Zipkin, Jeffrey Kroll Adams
-
Publication number: 20100278901Abstract: The present invention includes compositions and methods for reduce the taste of the drug in the drug resin complex. The composition may include one or more drug-resin complexes and a highly compressible, free-flowing pharmaceutical excipient. The resin is present in an amount effective to reduce the taste of the drug in the drug resin complex relative to an otherwise identical pharmaceutical composition without the resin; and wherein the highly compressible, free-flowing pharmaceutical excipient causes release of the drug-resin complex in the mouth.Type: ApplicationFiled: March 4, 2010Publication date: November 4, 2010Applicant: NEOS THERAPEUTICS, LPInventors: Mark TENGLER, Russell Lee McMahen
-
Publication number: 20100278933Abstract: The invention relates to kinase inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating disorders, especially cancer.Type: ApplicationFiled: June 5, 2008Publication date: November 4, 2010Applicant: University of Florida Research Foundation, IncInventors: Peter P. Sayeski, Gyƶrgy M. KeserĆ¼
-
Publication number: 20100272654Abstract: Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.Type: ApplicationFiled: July 9, 2010Publication date: October 28, 2010Inventors: Paul McGlynn, Roger Bakale, Craig Sturge
-
Publication number: 20100273822Abstract: Solid oral dosage immediate release compositions comprising strong acid ion exchange resins and methods for delivering drug formulations.Type: ApplicationFiled: April 21, 2010Publication date: October 28, 2010Inventors: William Wayne Howard, Russell Francis Somma
-
Publication number: 20100266699Abstract: A pharmaceutical suspension having a therapeutically effective amount of phenylephrine and a therapeutically effective amount of a first active agent consisting essentially of a first substantially water insoluble active agent having an average particle size of between about 10 and about 100 microns, an effective amount of non-reducing sweetener; an effective amount of water; and an effective amount of a suspending system; wherein the pharmaceutical suspension has a pH of from about 4 to about 6 and is substantially free of a reducing sugar and related methods.Type: ApplicationFiled: June 30, 2010Publication date: October 21, 2010Inventors: Gail K. Buehler, Edward A. Koch, Dana J. Rechen
-
Publication number: 20100267675Abstract: The present invention relates to stable compositions comprising a sphingosine 1 phosphate (S1P) receptor modulator, suitable for use as a dosage form. The S1P receptor modulators are typically sphingosine analogues, such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e.g. a compound comprising a group of formula Y.Type: ApplicationFiled: October 9, 2008Publication date: October 21, 2010Inventors: Colleen Ruegger, Michael Ambuhl
-
Publication number: 20100260669Abstract: Multi-dose active agent packages and methods for using the same for treating a subject for a condition are provided. Aspects of the invention include a multi-dose active agent package containing a plurality of unit dosage forms of an active agent configured to modulate at least a portion of a subject's autonomic nervous system during at least one season of the year. The active agent is present in an amount sufficient to alter the parasympathetic activity/sympathetic activity ratio of the subject in a manner effective to treat the subject for the condition. The subject active agent packages and methods find use in the treatment of a variety of different conditions, including disease conditions that increase in severity and/or occurrence during one or more seasons of the year. Also provided are kits for use in practicing the subject methods.Type: ApplicationFiled: April 15, 2010Publication date: October 14, 2010Inventors: Anthony Joonkyoo Yun, Patrick Yuarn-Bor Lee
-
Publication number: 20100260833Abstract: The invention relates to a solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid.Type: ApplicationFiled: June 24, 2010Publication date: October 14, 2010Applicant: GRUNENTHAL GMBHInventors: Johannes BARTHOLOMĆUS, Heinrich Kugelmann
-
Publication number: 20100260671Abstract: The invention is in general directed to compounds, such as tannic acid, nicotine, nicotine derivatives and pyrrolid derivatives of nicotine, and methods for diagnosing, preventing or alleviating the symptoms of amyloid-associated diseases, for example, neuronal diseases, such as, for example, Alzheimer's disease, compounds and methods for inhibiting ion channel activity of beta amyloid, and methods of diagnostic imaging of A/3 fibrils.Type: ApplicationFiled: May 30, 2008Publication date: October 14, 2010Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Jerry Yang, Petra Inbar, Mahealani Bautista, Michael Mayer
-
Publication number: 20100260835Abstract: A pharmaceutical composition comprising a moulded body of a polymer matrix, said polymer matrix comprising at least one polyaphron dispersion and at least one pharmaceutically active agent dispersed therein.Type: ApplicationFiled: June 26, 2008Publication date: October 14, 2010Inventors: Derek Alfred Wheeler, David Fraser Steele
-
Publication number: 20100260755Abstract: The invention contemplates methods and compositions for treating multiple sclerosis including the administration of a PDE inhibitor and at least one immunomodulator comprising mitoxantrone, natalizumab, fingolimod, laquinimod, cladribine, dimethylfumarate or a mixture comprising synthetic polypeptide analogs of myelin basic protein, including alanine, glutamic acid, lysine, and tyrosine amino acid residues, in a therapeutically effective amount. A preferred PDE inhibitor includes ibudilast.Type: ApplicationFiled: April 7, 2010Publication date: October 14, 2010Inventors: Richard E. GAMMANS, Kenneth W. Locke, Michael E. Kalafer
-
Publication number: 20100260717Abstract: Briefly described, embodiments of this disclosure include compositions, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of identifying a candidate agent for the treatment of hepatitis C virus (HCV) infection, and the like.Type: ApplicationFiled: September 18, 2008Publication date: October 14, 2010Inventors: Stephen R. Quake, Shirit Einav, Jeffrey S. Glenn, Robert McDowell, Wenjin Yang, Doron Gerber, Hadas Dvory-Sobol
-
Publication number: 20100260842Abstract: Controlled-release pharmaceutical formulations comprising pseudoephedrine or any of its pharmaceutically acceptable salts, processes for preparing the pharmaceutical formulations, and methods of using the formulations.Type: ApplicationFiled: April 6, 2010Publication date: October 14, 2010Inventors: Rashmi Nair, Praveen Raheja, Sanjay Chhagan Wagh, Raviraj Sukumar Pillai
-
Publication number: 20100254939Abstract: The present invention relates to graft copolymers of polyvinyl sulfonic-co-vinyl alcohol)-g-poly(lactide-co-glycolide) (P(VS-VA)-g-PLGA) with negatively charged electrolyte properties, their method of preparation and their use. These negatively charged graft copolymers are suitable for effective loading and sustained-release of especially positively charged drugs, proteins and peptides, and drug-loaded particles from these grafted co-polymers are especially useful as parenteral or mucosal drug delivery systems for pharmaceutical applications.Type: ApplicationFiled: September 8, 2008Publication date: October 7, 2010Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Thomas Kissel, Xiaoying Wang
-
Patent number: 7807854Abstract: To provide a medicament which efficiently expresses an immunosuppressive agent or an anti-inflammatory agent and reduces expression of side effect. A medicament includes diaryl sulfide or diaryl ether compound having a 2-amino-1,3-propanediol structure having an activity of reducing lymphocytes circulating peripherally, in combination with an immunosuppressive agent and/or an anti-inflammatory agent.Type: GrantFiled: December 31, 2009Date of Patent: October 5, 2010Assignee: Kyorin Pharmaceutical Co., Ltd.Inventors: Shinji Kudou, Kazuhiko Kuriyama, Tokutarou Yasue
-
Publication number: 20100240617Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.Type: ApplicationFiled: February 15, 2010Publication date: September 23, 2010Inventors: Kevin R. Lynch, Timothy L. MacDonald, Kevin Guckian, Edward Yin-shiang Lin, Bin Ma
-
Publication number: 20100240764Abstract: The use of S-Clenbuterol for restoring and/or maintaining the function of partially or completely damaged/degenerated cells in the central nervous system and/or other nerve cells is claimed. The use of S-Clenbuterol leads to activation of astrocytes and initiation of endogenous processes of neuroprotection, it thus being possible for the damage or destruction of nerve cells to be reduced and, in some cases, even prevented.Type: ApplicationFiled: February 1, 2006Publication date: September 23, 2010Applicant: EUCRO EUROPEAN CONTRACT RESEARCH GMBH & CO. KGInventors: Wolfgang Greb, Josef Krieglstein, Carsten Culmsee
-
Publication number: 20100227867Abstract: In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: wherein each of R1, R2, and R3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R4 and R5 is independently hydrogen, alkyl, or alkoxy; and each of R6 and R7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A1, A3, and A4 is independently hydrogen or alkyl; and A2 is independently hydrogen or hydroxy; and wherein each of B1, B2, and B3 is independently hydrogen, hydroxy, or alkoxy; and each of B4 and B5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat inflammatory skin disorders and the symptoms associated therewith.Type: ApplicationFiled: August 21, 2009Publication date: September 9, 2010Applicant: Galderma Laboratories Inc.Inventors: Jack A. DeJovin, Isabelle Jean DeJovin, Thomas M. Rossi
-
Publication number: 20100222298Abstract: The invention relates to novel spill resistant formulations comprising either a weak base or a weak acid as the pharmaceutical ingredient, a liquid base, a clay and a water soluble cellulose ether. The clay and cellulose ether allow for a broader pH range into which the pharmaceutically active agent may be dispersed or dissolved, and therefore allows for easier preparation and formulation of the pharmaceutical composition.Type: ApplicationFiled: May 13, 2010Publication date: September 2, 2010Applicant: Taro Pharmaceuticals U.S.A., Inc.Inventors: Satish ASOTRA, Xiaoli WANG, Zoltan BODOR
-
Publication number: 20100222257Abstract: Disclosed herein are substituted phenethylamine alpha adrenergic receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: May 17, 2010Publication date: September 2, 2010Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Patent number: 7786173Abstract: Tetralin analogs that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs, which, after phosphorylation, can behave as agonists at S1P receptors.Type: GrantFiled: May 21, 2009Date of Patent: August 31, 2010Assignee: University of Virginia Patent FoundationInventors: Kevin R. Lynch, Timothy L. Macdonald